ERC Starting Grant · 2024
Deciphering host-microbiome interactions in anti-cancer immunity
Despite unprecedented clinical success, T cell-based immunotherapies present significant heterogeneity in response rates, often attributed to dampened activation and limited tumour infiltration of CD8+ T cells. Studies in mice and humans have shown that gut commensals can modulate anti-cancer immune responses dictating the efficacy of immunotherapy, but have failed to identify species that are consistently associated with improved patient prognosis. I recently made a breakthrough in our efforts to understand the host determinants that define microbiome-dependent cancer immunity. I discovered that a single micronutrient, vitamin D (vitD), enhances the ability of the gut microbiome to induce…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.